Pharmaceutical Executive September 19, 2025
Key Takeaways
- Biogen’s acquisition of Alcyone Therapeutics focuses on advancing the ThecaFlex DRx system for intrathecal delivery of antisense oligonucleotides.
- The ThecaFlex DRx system provides an alternative to lumbar punctures, offering a patient-centered solution for cerebrospinal fluid access.
- Biogen will manage the development, commercialization, and manufacturing of ThecaFlex DRx, integrating Alcyone employees into its product delivery solutions team.
- Alcyone receives $85 million upfront, with additional milestone payments, while its remaining assets are divested into Neela Therapeutics.
Biogen expands its drug delivery solutions by acquiring Alcyone Therapeutics, enhancing patient-centered therapies with the innovative ThecaFlex DRx system.
Biogen acquired Alcyone Therapeutics with the intention to expand its drug delivery solution portfolio along with advancing ThecaFlex DRx, an implantable subcutaneous port...
Today's Sponsors
Today's Sponsor